Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2007-11-13 Interim / Quarterly Rep…
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Q3 Report 2007
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Evotec AG, Third Quarter Report 2007' and contains detailed financial statements, management discussion and analysis (MDA) of the first nine months of 2007, revenue breakdowns, and operational highlights. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2007
2007-11-13 German
Corporate Presentation October 2007
M&A Activity Classification · 98% confidence The document discusses a proposed merger/business combination between Evotec and Renovis. Key indicators are the mention of an 'Agreement and Plan of Merger', the filing of a 'Current Report on Form 8-K' by Renovis, and the intent by Evotec to file a 'Registration Statement on Form F-4'. These documents (8-K, F-4, joint proxy statement/prospectus) are all directly related to a significant corporate transaction, specifically a merger or takeover bid. This aligns perfectly with the definition for M&A Activity (TAR). Although the document mentions SEC filings like 10-K and 10-Q in the forward-looking statements section, the primary subject matter and context of the entire document is the transaction itself, not the periodic financial reports themselves. The document is an announcement or presentation detailing the terms and rationale of the merger.
2007-10-10 English
Evotec to Acquire Renovis, Seek NASDAQ Listing
M&A Activity Classification · 98% confidence The document discusses a proposed business combination transaction (merger) between Evotec and Renovis. It contains extensive forward-looking statements, details about the exchange ratio, post-merger pro-forma figures, and transaction closing conditions, including expected shareholder votes (Q4 2007 / Q1 2008). Crucially, it mentions that Renovis is filing a Current Report on Form 8-K which will include the Agreement and Plan of Merger, and Evotec intends to file a Registration Statement on Form F-4, which will include a joint proxy statement/prospectus. The mention of a merger proposal, exchange of shares, and the filing of documents related to a takeover bid strongly points towards the M&A Activity category (TAR). While it mentions SEC filings like 8-K and F-4, the core subject is the merger proposal itself, making TAR more specific than a general Regulatory Filing (RNS) or a Proxy Solicitation (PSI), as it details the terms of the takeover/merger.
2007-09-19 English
Sale of the Chemical Development Business to Aptuit
Capital/Financing Update Classification · 98% confidence The document discusses a strategic transaction: the divestment (sale) of a non-core business unit (Chemical Development) to another company (Aptuit) for a specific cash amount (£ 31.5m). It details the rationale for the transaction, the assets being sold, and the impact on the company's focus (concentrating on higher value pipeline expansion). This content strongly aligns with announcements regarding corporate restructuring, financing, or significant asset transactions, which falls under the 'Capital/Financing Update' category, as it involves a major cash inflow from a divestiture. It is not a standard periodic report (10-K, IR, ER), nor is it a management discussion (MDA) of results, but rather a specific corporate action announcement. Therefore, 'CAP' (Capital/Financing Update) is the most appropriate classification.
2007-09-11 English
Q2 Report 2007
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Evotec AG, Half Year Report 2007' and contains detailed financial performance data, including revenue analysis, operating loss, net loss, and cash position for the first half of the fiscal year. It includes an 'Interim Management Report' section and discusses business strategy, pipeline progress, and financial results. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2007
2007-08-14 German
Corporate Presentation June 2007
Investor Presentation Classification · 98% confidence The document text is structured like a presentation, containing slides, agendas, bullet points highlighting company performance ('Evotec highlights'), pipeline details ('CNS Pipeline'), and clinical trial summaries ('EVT 201: Clinical Development Summary'). The presence of 'Forward-looking statements' and an 'Agenda' strongly suggests this is an Investor Presentation (IP) or a similar strategic overview document, rather than a formal regulatory filing (like 10-K, AR, or ER) or a short announcement (RPA/RNS). The content focuses on strategy, pipeline, and financial outlook, which aligns perfectly with the definition of an Investor Presentation.
2007-06-12 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.